ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France


No votes yet
 
Related
ROVI achieves a 10% increase in operating income and 55% in net profit
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research,...
5 min
24/02/2021